SI3826667T1 - Protitelesa Claudin6 in metode zdravljenja raka - Google Patents

Protitelesa Claudin6 in metode zdravljenja raka

Info

Publication number: SI3826667T1
Authority: SI; Slovenia
Prior art keywords: claudin6; antibodies; cancer treatment; treatment methods; cancer
Prior art date: 2017-09-18

Application number

SI201831128T

Other languages

English (en)

Inventor

Dylan Conklin

Dennis Slamon

Neil O'brien

Mike Palazzolo

Euw Erika Von

Original Assignee

The Regents Of The University Of California

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-09-18

Filing date

2018-09-18

Publication date

2024-09-30

2018-09-18 Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California

2024-09-30 Publication of SI3826667T1 publication Critical patent/SI3826667T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Oncology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Mycology (AREA)
Hospice & Palliative Care (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)
Pathology (AREA)
Plant Pathology (AREA)

SI201831128T 2017-09-18 2018-09-18 Protitelesa Claudin6 in metode zdravljenja raka SI3826667T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201762560143P	2017-09-18	2017-09-18
PCT/US2018/051610 WO2019056023A2 (en)	2017-09-18	2018-09-18	ANTIBODIES AGAINST CLAUDIN 6 AND METHODS OF TREATING CANCER
EP18857242.4A EP3826667B1 (en)	2017-09-18	2018-09-18	Claudin6 antibodies and methods of treating cancer

Publications (1)

Publication Number	Publication Date
SI3826667T1 true SI3826667T1 (sl)	2024-09-30

Family

ID=65723110

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201831128T SI3826667T1 (sl)	2017-09-18	2018-09-18	Protitelesa Claudin6 in metode zdravljenja raka

Country Status (22)

Country	Link
US (4)	US20200291111A1 (sl)
EP (2)	EP3826667B1 (sl)
JP (2)	JP7599332B2 (sl)
KR (2)	KR102793719B1 (sl)
CN (2)	CN111565744B (sl)
AU (2)	AU2018334434B2 (sl)
BR (1)	BR112020005196A2 (sl)
CA (1)	CA3076207A1 (sl)
CZ (1)	CZ2021138A3 (sl)
DK (1)	DK3826667T3 (sl)
ES (1)	ES2986343T3 (sl)
FI (1)	FI3826667T3 (sl)
GB (1)	GB202103867D0 (sl)
HU (1)	HUE067603T2 (sl)
IL (2)	IL313238A (sl)
MX (2)	MX2020002921A (sl)
NO (1)	NO20210351A1 (sl)
PL (1)	PL3826667T3 (sl)
PT (1)	PT3826667T (sl)
SG (1)	SG11202002114RA (sl)
SI (1)	SI3826667T1 (sl)
WO (1)	WO2019056023A2 (sl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN111565744B (zh) *	2017-09-18	2024-12-31	加利福尼亚大学董事会	紧密连接蛋白6抗体和治疗癌症的方法
IL301638B2 (en)	2017-09-29	2024-09-01	Daiichi Sankyo Co Ltd	Antibody-pyrrolobenzodiazepine derivative conjugate
KR102063341B1 (ko) *	2018-12-31	2020-01-07	다이노나(주)	Icam-1에 특이적으로 결합하는 항체 및 그의 용도
KR20210128443A (ko)	2019-02-15	2021-10-26	인테그럴 몰큘러 인코포레이티드	클라우딘 6 항체 및 이의 용도
JP7682797B2 (ja) *	2019-03-20	2025-05-26	ザリージェンツオブザユニバーシティオブカリフォルニア	クローディン６二重特異性抗体
MX2021011330A (es)	2019-03-20	2021-12-10	Univ California	Anticuerpos de claudina-6 y conjugados de fármacos.
JP2023529557A (ja) *	2020-05-04	2023-07-11	ザリージェンツオブザユニバーシティオブカリフォルニア	抗ｅｎｐｐ１抗体の阻害
CN112386687B (zh) *	2020-12-09	2021-05-04	爱龄医美国际健康咨询服务(北京)有限公司	一种干细胞外泌体及其在药品和化妆品中的应用
US20250042996A1 (en) *	2021-11-16	2025-02-06	Christopher Bebbington	Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
KR20240153421A (ko) *	2022-02-09	2024-10-22	세라 프로그노스틱스 인코포레이티드	Shbg 및 ibp4 항체 및 이를 사용하는 방법
IL319951A (en)	2022-11-30	2025-05-01	Integral Molecular Inc	Antibodies targeting claudin 6, including its bispecific formats
WO2024243561A1 (en)	2023-05-25	2024-11-28	The Regents Of The University Of California	Methods of treating cancer
WO2025075127A1 (ja) *	2023-10-04	2025-04-10	公立大学法人福島県立医科大学	がんのバイオマーカー及び抗体治療
WO2025146161A1 (en) *	2024-01-04	2025-07-10	Hansoh Bio Llc	Antibody, antigen-binding fragment and medical use thereof
WO2025162270A1 (zh) *	2024-02-01	2025-08-07	江苏恒瑞医药股份有限公司	抗cldn6抗体、其抗体-药物偶联物及其医药用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4450150A (en)	1973-05-17	1984-05-22	Arthur D. Little, Inc.	Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4526988A (en)	1983-03-10	1985-07-02	Eli Lilly And Company	Difluoro antivirals and intermediate therefor
DE3587500T2 (de)	1984-12-04	1993-12-16	Lilly Co Eli	Tumorbehandlung bei Säugetieren.
CN1296417A (zh)	1998-02-10	2001-05-23	卫福有限公司	控释制剂
JP2003530297A (ja)	1998-10-16	2003-10-14	ザガバメントオブザユナイテッドステイツオブアメリカ，リプリゼンテッドバイザセクレタリーオブザデパートメントオブヘルスアンドヒューマンサービシーズ	Ｖｉｐアンタゴニストを用いる併用療法
GB2344287A (en)	1998-12-03	2000-06-07	Ferring Bv	Controlled release pharmaceutical formulation
JP2004511425A (ja)	2000-02-08	2004-04-15	ザ　ペン　ステート　リサーチ　ファウンデーション	免疫療法に使用されるインターロイキン１３受容体サブユニットアルファー２
US7771951B2 (en)	2001-12-03	2010-08-10	Amgen Fremont Inc.	Antibody categorization based on binding characteristics
DE60331455D1 (de)	2002-10-04	2010-04-08	Microchips Inc	Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
AU2007332473B2 (en) *	2006-12-14	2012-09-27	Forerunner Pharma Research Co., Ltd.	Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
NZ580700A (en)	2007-04-19	2012-01-12	Dong A Pharm Co Ltd	A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
SG187457A1 (en) *	2008-01-11	2013-02-28	Univ Tokyo	Anti-cldn6 antibody
EP2404936A1 (en)	2010-07-06	2012-01-11	Ganymed Pharmaceuticals AG	Cancer therapy using CLDN6 target-directed antibodies in vivo
JP6276176B2 (ja)	2011-05-13	2018-02-07	ガニメドファーマシューティカルズゲーエムベーハー	癌の治療のための抗体
WO2015014376A1 (en) *	2013-07-31	2015-02-05	Biontech Ag	Diagnosis and therapy of cancer involving cancer stem cells
RU2016122041A (ru) *	2013-11-06	2017-12-11	ЭББВИ СТЕМСЕНТРКС ЭлЭлСи	Новые анти-клаудин антитела и способы их применения
SI3514172T1 (sl)	2014-04-01	2020-07-31	Biontech Cell & Gene Therapies Gmbh	Claudin-6 specifični imunoreceptorji in T-celični epitopi
CN111565744B (zh) *	2017-09-18	2024-12-31	加利福尼亚大学董事会	紧密连接蛋白6抗体和治疗癌症的方法

2018
- 2018-09-18 CN CN201880073220.3A patent/CN111565744B/zh active Active
- 2018-09-18 CA CA3076207A patent/CA3076207A1/en active Pending
- 2018-09-18 WO PCT/US2018/051610 patent/WO2019056023A2/en not_active Ceased
- 2018-09-18 MX MX2020002921A patent/MX2020002921A/es unknown
- 2018-09-18 NO NO20210351A patent/NO20210351A1/en not_active Application Discontinuation
- 2018-09-18 PT PT188572424T patent/PT3826667T/pt unknown
- 2018-09-18 GB GBGB2103867.4A patent/GB202103867D0/en active Pending
- 2018-09-18 AU AU2018334434A patent/AU2018334434B2/en active Active
- 2018-09-18 FI FIEP18857242.4T patent/FI3826667T3/fi active
- 2018-09-18 DK DK18857242.4T patent/DK3826667T3/da active
- 2018-09-18 EP EP18857242.4A patent/EP3826667B1/en active Active
- 2018-09-18 PL PL18857242.4T patent/PL3826667T3/pl unknown
- 2018-09-18 US US16/648,428 patent/US20200291111A1/en not_active Abandoned
- 2018-09-18 IL IL313238A patent/IL313238A/en unknown
- 2018-09-18 CN CN202410853420.8A patent/CN118667021A/zh active Pending
- 2018-09-18 EP EP24169481.9A patent/EP4435009A3/en active Pending
- 2018-09-18 IL IL273196A patent/IL273196B2/en unknown
- 2018-09-18 KR KR1020207009742A patent/KR102793719B1/ko active Active
- 2018-09-18 ES ES18857242T patent/ES2986343T3/es active Active
- 2018-09-18 SG SG11202002114RA patent/SG11202002114RA/en unknown
- 2018-09-18 JP JP2020515692A patent/JP7599332B2/ja active Active
- 2018-09-18 KR KR1020257011014A patent/KR20250050137A/ko active Pending
- 2018-09-18 BR BR112020005196-9A patent/BR112020005196A2/pt unknown
- 2018-09-18 SI SI201831128T patent/SI3826667T1/sl unknown
- 2018-09-18 HU HUE18857242A patent/HUE067603T2/hu unknown
2020
- 2020-03-17 MX MX2025012685A patent/MX2025012685A/es unknown
2021
- 2021-03-19 CZ CZ2021138A patent/CZ2021138A3/cs unknown
2022
- 2022-04-13 US US17/719,609 patent/US20220372134A1/en not_active Abandoned
2023
- 2023-12-19 US US18/545,890 patent/US20240400674A1/en not_active Abandoned
2024
- 2024-06-20 JP JP2024099523A patent/JP2024150445A/ja active Pending
2025
- 2025-01-23 AU AU2025200467A patent/AU2025200467A1/en active Pending
- 2025-06-27 US US19/252,512 patent/US20250333501A1/en active Pending

Also Published As

Publication number	Publication date
SG11202002114RA (en)	2020-04-29
AU2018334434B2 (en)	2025-01-23
IL273196B1 (en)	2024-07-01
NO20210351A1 (en)	2021-03-18
JP2024150445A (ja)	2024-10-23
US20250333501A1 (en)	2025-10-30
GB202103867D0 (en)	2021-05-05
PL3826667T3 (pl)	2024-09-30
US20240400674A1 (en)	2024-12-05
KR102793719B1 (ko)	2025-04-08
PT3826667T (pt)	2024-08-02
US20200291111A1 (en)	2020-09-17
CA3076207A1 (en)	2019-03-21
JP7599332B2 (ja)	2024-12-13
IL313238A (en)	2024-07-01
WO2019056023A3 (en)	2019-05-16
MX2020002921A (es)	2020-09-28
ES2986343T3 (es)	2024-11-11
EP3826667A4 (en)	2022-07-27
MX2025012685A (es)	2025-11-03
KR20250050137A (ko)	2025-04-14
FI3826667T3 (fi)	2024-07-22
CN111565744A (zh)	2020-08-21
CN118667021A (zh)	2024-09-20
IL273196B2 (en)	2024-11-01
AU2025200467A1 (en)	2025-04-10
WO2019056023A2 (en)	2019-03-21
KR20200070238A (ko)	2020-06-17
CZ2021138A3 (cs)	2021-09-15
CN111565744B (zh)	2024-12-31
EP3826667B1 (en)	2024-04-17
EP3826667A2 (en)	2021-06-02
US20220372134A1 (en)	2022-11-24
EP4435009A2 (en)	2024-09-25
DK3826667T3 (da)	2024-07-22
HUE067603T2 (hu)	2024-10-28
JP2020536507A (ja)	2020-12-17
AU2018334434A1 (en)	2020-04-02
IL273196A (en)	2020-04-30
BR112020005196A2 (pt)	2020-09-15
EP4435009A3 (en)	2025-02-26

Publication	Publication Date	Title
SI3826667T1 (sl)	2024-09-30	Protitelesa Claudin6 in metode zdravljenja raka
IL272470A (en)	2020-03-31	Methods and materials for assessing and treating cancer
IL269150A (en)	2019-11-28	Compositions and methods for treating cancer
SI3383916T1 (sl)	2022-06-30	Protitelesa proti-CD73 in njihove uporabe
IL262092A (en)	2018-11-29	Humanized anti-pacap antibodies and uses thereof
IL258955A (en)	2018-06-28	Compositions and methods for treatment of cancer
IL263224A (en)	2018-12-31	Methods and compositions for treating cancers
IL268814A (en)	2019-10-31	Compositions and methods for treatment of cancer
SI3515487T1 (sl)	2023-09-29	Bispecifična protitelesa proti-MUC16-CD3 in konjugati zdravil proti-MUC16
PL3303632T3 (pl)	2020-07-13	Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze
SI3274370T1 (sl)	2020-02-28	Protitelesa proti CEACAM6 in njihova uporaba
SI3347379T1 (sl)	2020-04-30	ANTI-TIGIT protitelesa, ANTI-PVRIG protitelesa in njihove kombinacije
DK3504242T3 (da)	2020-08-17	Anti-ox40-antistoffer og anvendelse deraf
PL3943093T3 (pl)	2025-09-01	Zastosowanie pasteryzowanej akkermansia do leczenia nowotworu złośliwego
DK3458478T3 (da)	2021-03-22	Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
DK3283106T3 (da)	2022-01-10	Terapeutiske antistoffer og anvendelser deraf
SI3134124T1 (sl)	2019-06-28	Konjugat protitelesa zdravila IGF-1R in uporaba le-tega za zdravljenje raka
SI3303394T1 (sl)	2020-10-30	Protitelesa proti-CTLA-4 in postopki njihove uporabe
DK3134125T3 (da)	2020-01-13	Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer
DK3624837T3 (da)	2025-09-29	Anti-fgfr2-antistoffer i kombination med kemoterapeutiske midler til kræftbehandling
IL251759B (en)	2021-01-31	Compositions and methods for treating insomnia
IL271326A (en)	2020-01-30	Compositions and methods for enhancing cancer radiotherapy
IL269157A (en)	2019-11-28	Compositions and methods for treating cancer
DK3253800T3 (da)	2021-05-31	Prostata antigen standarder og bruge deraf
PL3490560T3 (pl)	2025-03-24	Niraparyb do stosowania w sposobie leczenia nowotworu prostaty